Unigestion Holding SA Purchases New Shares in Gilead Sciences, Inc. (NASDAQ:GILD)

Unigestion Holding SA acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 38,596 shares of the biopharmaceutical company's stock, valued at approximately $4,325,000.

Other large investors have also recently added to or reduced their stakes in the company. Bridgewater Associates LP raised its stake in shares of Gilead Sciences by 122.7% during the fourth quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock valued at $42,577,000 after purchasing an additional 253,994 shares in the last quarter. Nissay Asset Management Corp Japan ADV lifted its stake in shares of Gilead Sciences by 5.2% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after acquiring an additional 14,009 shares during the period. Jennison Associates LLC bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $87,163,000. Columbus Macro LLC increased its position in shares of Gilead Sciences by 55.9% during the 4th quarter. Columbus Macro LLC now owns 25,103 shares of the biopharmaceutical company's stock valued at $2,319,000 after purchasing an additional 9,004 shares during the period. Finally, NatWest Group plc bought a new stake in Gilead Sciences in the fourth quarter worth about $6,808,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on GILD shares. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Bank of America raised their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and boosted their target price for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Cantor Fitzgerald assumed coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target on the stock. Finally, Oppenheimer decreased their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $110.55.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the sale, the chief financial officer now directly owns 165,674 shares in the company, valued at approximately $16,537,578.68. The trade was a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider now owns 121,152 shares of the company's stock, valued at $13,026,263.04. This trade represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 60,929 shares of company stock worth $6,748,980 in the last quarter. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Stock Down 0.3%

NASDAQ:GILD traded down $0.31 during trading hours on Wednesday, reaching $109.02. The company's stock had a trading volume of 7,963,204 shares, compared to its average volume of 7,730,101. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96. The business's 50-day moving average is $105.45 and its 200-day moving average is $101.10. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a market cap of $135.61 billion, a price-to-earnings ratio of 294.65, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm's revenue was down .3% compared to the same quarter last year. During the same period last year, the business earned ($1.32) EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.90%. Gilead Sciences's payout ratio is presently 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.